Top Story Today
A Patient's Liver Got Hammered. Now the Entire CRISPR Sector Is on Edge.
Intellia Therapeutics, the most advanced company delivering CRISPR edits directly inside the human body, saw the FDA place clinical holds on two late-stage trials after a patient experienced severe liver toxicity. The patient reportedly died of septic shock following complications. The holds have since been lifted after Intellia agreed to enhanced monitoring and tighter patient criteria, but the damage to investor confidence is real: Goldman Sachs cut the stock to Sell while Evercore upgraded it, and shares remain pinned near lows. Intellia's separate hereditary angioedema program is unaffected, but the episode has amplified scrutiny on every in vivo gene-editing company.
Why it matters: A serious adverse event in the most advanced in vivo CRISPR program raises the bar for every gene-editing therapy behind it, reinforcing that permanently rewriting human DNA inside the body requires proving both extraordinary efficacy and extraordinary safety.
Read more →Clinical Wins and Losses
The Melanoma Drug the FDA Rejected Twice Just Got Approved
Replimune's oncolytic virus therapy Tudriqev earned accelerated approval for advanced melanoma on August 6th. The turnaround came after an advisory committee voted that the data were "clinically meaningful." It's the first new oncolytic virus approval for melanoma in years and a credibility boost for the entire viral therapy class.
Read more →Merck's $10.8 Billion Drug Aced Skin Disease, Then Flopped in the Lungs
Tulisokibart delivered a clean Phase 2 win in hidradenitis suppurativa but missed its primary endpoint entirely in systemic sclerosis lung disease. Merck is killing the lung program. The split verdict narrows the drug's potential footprint but keeps Merck's core thesis alive: TL1A blockade still works in the gut and on the skin, where competition is fierce.
Read more →BioMarin Writes Off $270 Million After Its Biomarker Moved but Patients Didn't Improve
BioMarin's BMN 401 hit its biochemical target in a Phase 3 trial for ENPP1 deficiency but failed to show any clinical improvement in children's rickets, growth, or disease severity. The company scrapped the program entirely, turning its $270 million Inozyme acquisition into an expensive science experiment. Shares dipped about 2.3%.
Read more →Science and Discovery
A Gene Editor Just Destroyed Hepatitis B's Hidden Reservoir in a Human Liver
Precision BioSciences presented biopsy data showing its ARCUS-based gene editor eliminated nearly all cccDNA (the viral blueprint that makes hep B incurable) in a patient's liver. It's the first clinical evidence any gene-editing therapy can destroy that reservoir directly, offering a potential path toward a functional cure for 254 million chronic HBV patients worldwide.
Read more →CAR-T Therapy Went 20 for 20 in Patients Who Don't Even Have Cancer Yet
A Dana-Farber trial treated 20 high-risk smoldering myeloma patients with Carvykti before they developed full-blown cancer. Every single patient hit MRD negativity within two months and none progressed, though some experienced grade 3/4 toxicities including neutropenia. It's the strongest evidence yet that deploying CAR-T earlier (not as a last resort) could fundamentally change cancer treatment.
Read more →Policy and Funding
The FDA Picked a Fight With Moderna's Flu Shot, and the Whole Vaccine Industry Flinched
The FDA refused to review Moderna's mRNA flu vaccine because the agency retroactively objected to the trial's comparison vaccine, a choice that was never flagged before the study ran. A senior official reportedly overruled career scientists. The decision was eventually reversed, with approval granted for adults 50+, but experts warn the episode's chilling effect on vaccine investment may outlast the reversal.
Read more →NIH Plans to Block Visa-Holding Researchers From a Key Career Grant
The NIH reportedly plans to exclude visa-holding researchers from the K99/R00 grant, one of the only major funding pathways still open to international postdocs. With roughly half of all U.S. biomedical postdocs on temporary visas, the move could accelerate a brain drain at a time when NIH budgets are already under historic pressure.
Read more →